Generali Investments CEE investicni spolecnost a.s. Makes New $601,000 Investment in Illumina, Inc. (NASDAQ:ILMN)

Generali Investments CEE investicni spolecnost a.s. bought a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 4,500 shares of the life sciences company’s stock, valued at approximately $601,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of ILMN. WCM Investment Management LLC raised its stake in Illumina by 26.6% during the fourth quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company’s stock valued at $551,625,000 after purchasing an additional 867,673 shares in the last quarter. Bank of New York Mellon Corp raised its position in shares of Illumina by 0.8% during the 4th quarter. Bank of New York Mellon Corp now owns 3,402,057 shares of the life sciences company’s stock valued at $454,617,000 after buying an additional 27,618 shares in the last quarter. Geode Capital Management LLC lifted its holdings in shares of Illumina by 1.8% in the 3rd quarter. Geode Capital Management LLC now owns 2,727,827 shares of the life sciences company’s stock valued at $354,933,000 after acquiring an additional 48,018 shares during the last quarter. Primecap Management Co. CA grew its position in Illumina by 3.6% in the third quarter. Primecap Management Co. CA now owns 2,516,359 shares of the life sciences company’s stock worth $328,158,000 after acquiring an additional 87,599 shares in the last quarter. Finally, Janus Henderson Group PLC grew its position in Illumina by 40.5% in the third quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company’s stock worth $282,735,000 after acquiring an additional 625,245 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on ILMN shares. TD Cowen lowered Illumina from a “buy” rating to a “hold” rating and lowered their price objective for the company from $177.00 to $140.00 in a research note on Friday, February 7th. Canaccord Genuity Group lowered their price target on Illumina from $145.00 to $135.00 and set a “hold” rating for the company in a research report on Friday, February 7th. Guggenheim cut their price objective on shares of Illumina from $170.00 to $150.00 and set a “buy” rating on the stock in a research report on Friday, February 7th. Robert W. Baird lowered their target price on shares of Illumina from $127.00 to $90.00 and set a “neutral” rating for the company in a report on Wednesday. Finally, Hsbc Global Res cut shares of Illumina from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 28th. One analyst has rated the stock with a sell rating, ten have given a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $149.25.

Illumina Trading Up 2.3 %

NASDAQ:ILMN opened at $86.62 on Friday. The firm has a 50-day simple moving average of $118.38 and a 200-day simple moving average of $131.49. Illumina, Inc. has a one year low of $80.18 and a one year high of $156.66. The firm has a market cap of $13.72 billion, a P/E ratio of -11.28, a P/E/G ratio of 1.60 and a beta of 1.17. The company has a debt-to-equity ratio of 0.63, a quick ratio of 1.42 and a current ratio of 1.77.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. Equities analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.